人脐带血来源的间充质干细胞特性及对卵巢癌细胞趋化作用的研究

The characteristics of mesenchymal stem cells derived from human umbilical cord blood and its chemotaxis in ovarian cancer cells

目的为人脐带血(HUCD)可成为间充质干细胞(MSCs)重要新来源提供依据,着重研究对人卵巢癌细胞的趋化作用,为临床靶向治疗卵巢癌提供新的载体。方法征求足月健康的自然产孕妇同意,获得脐带血,从中提取MSCs。获得稳定增殖传代的MSCs后,鉴定其生物特性和抗原表型,将其与人卵巢癌HO-8910细胞共培养,探讨其对卵巢癌细胞的趋化作用。结果成功从HUCD中提取MSCs,筛选出稳定传代的细胞系。其生物学特性与骨髓来源的MSCs一样具有多向细胞分化潜能,可诱导分化成脂肪细胞、成骨细胞;同时还具有相同的免疫表型,CD29、CD44、CD105阳性表达,CD13、CD14、CD34、CD45阴性表达,并且其免疫表型不随着细胞传代而改变。HUCD来源的MSCs与HO-8910细胞共培养时发现,MSCs对其有趋化作用。结论证实HUCD可以作为MSCs的新的重要来源。实验发现MSCs对人卵巢癌细胞株HO-8910有明显趋化作用,这一发现可能为卵巢肿瘤靶向治疗提供了新的有效载体。

Objective： To provide evidence on human umbilical cord blood （HUCD） that can be a new important origin of mesenchymal stem cells （MSCs）.Mainly research the MSCs＇s ability of the chemotaxis to ovarian cancer cells,which can become the new target-vector of ovarian cancers on clinical therapy.Methods： We obtain HUCD from mature and healthy pregnant woman who agreed as parturition.Isolate,purify and culture MSCs,till MSCs have a stable proliferation,identify biology characteristic and phenotypic characterization.Then have a co-culture with the human ovarian carcinoma cell lines HO-8910,the tropism capacity of MSCs was quantitatively assayed in vitro using the Millicell system.Results： MSCs obtained from HUCD,which have the same biology characteristic and phenotypic characterization with that originated from bone marrow.HUCD MSCs can differentiate into lipocyte and osteoblast.HUCD MSCs don＇t expressed hematopoietic cell-related antigen CD13,CD14,CD34,CD45,but the MSCs-ralated antigen CD29,CD44,CD105,which don＇t change by generation passaged.We can see the migratory capacity of MSCs toward HO-8910 cells,when HO-8910 cells were cocultured with HUCD MSCs in Millicell for 48 h.Conclusions： It is identified that HUCD can be a new important origin of MSCs,which have the same biology characteristic and phenotypic characterization with that resource from bone marrow.The results provided evidence that MSCs have the ability of the chemotaxis to human ovarian carcinoma cells,and we may find a new effective target-vector in carcinoma therapy.